Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat

NMR in Biomedicine

Volumn 22, Issue 4, 2009, Pages 419-425

  Perrine, Shane A ^a   Michaels, Mark S ^a   Ghoddoussi, Farhad ^a   Hyde, Elisabeth M ^a   Tancer, Manuel E ^a   Galloway, Matthew P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carnitine; Heart; Magnetic resonance spectroscopy; MDMA; Rat; Serotonin

Indexed keywords

BODY TEMPERATURE; CARDIAC PHYSIOLOGY; CARDIAC TISSUES; CARDIOMYOCYTES; CARNITINE; ENERGY REGULATION; FATTY ACID METABOLISM; HEART; HEART RATES; HEART TISSUES; HEART WALL; HIGH RESOLUTION MAGIC ANGLE SPINNING; LEFT VENTRICULAR; MDMA; METABOLIC PROFILES; METABOLOMICS; METHYLENEDIOXYMETHAMPHETAMINE; PROTON MAGNETIC RESONANCE SPECTROSCOPIES; SEMI-SOLID MATERIALS; SEROTONIN; TISSUE SAMPLES;

AMINO ACIDS; ANIMALS; BIOCHEMISTRY; BLOOD PRESSURE; CHROMATOGRAPHIC ANALYSIS; ENERGY POLICY; FATTY ACIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LAWS AND LEGISLATION; MAGNETIC RESONANCE; METABOLISM; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE DETECTORS; PHYSIOLOGY; PROTONS; RATS; SPECTROSCOPY; TISSUE;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALANINE; CARNITINE; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; LACTIC ACID; NORADRENALIN; SEROTONIN; SUCCINIC ACID; TAURINE; PROTON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE MEASUREMENT; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; DOSE RESPONSE; DRUG EXPOSURE; FATTY ACID METABOLISM; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS AND REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ANIMAL; ANTIBODY SPECIFICITY; BODY TEMPERATURE; DRUG EFFECT; HEART; MALE; METABOLISM; METABOLOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; BODY TEMPERATURE; CHOLINE; HEART; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MYOCYTES, CARDIAC; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; ORGAN SPECIFICITY; PROTONS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 67649173003     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1352     Document Type: Article

References (47)

1. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J. Pharmacol. Exp. Ther. 2002; 302(3): 898-907.
2. O'Cain PA, Hletko SB, Ogden BA, Varner KJ. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol. Behav. 2000; 70(1-2): 141-148.
3. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A. double-blind, placebo-controlled trial. Ann. Int. Med. 2000; 133(12): 969-973.
4. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 1999; 290(1): 136-145.
5. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl.) 2007; 189(4): 565-573.
6. NIDA. Monitoring the Future: National Results on Adolescent Drug Use, National Institute on Drug Abuse, Bethesda, Maryland 20892. 2004.
7. SAMHSA. Drug Abuse Warning Network 2003. Interim National Estimates of Drug-Related Emergency Department Visits, Substance Abuse and Mental Health Services Administration. Office of Applied Studies: Rockville, MD, 2004.
8. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Ther. 2002; 300(3): 1093-1100.
9. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 2006; 319(1): 237-246.
10. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 1993; 44(6): 1227-1231.
11. Leonardi ET, Azmitia EC. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994; 10(4): 231-238.
12. Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl.) 1986; 88(4): 525-526.
13. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 1987; 240(1): 1-7.
14. Ricaurte GA. Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. NIDA Res. Monogr. 1989; 94: 306-322.
15. McCann UD, Eligulashvili V, Ricaurte GA. (+/ -)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000; 42(1): 11-16.
16. Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 2006; 111(3): 674-706.
17. Ni W, Watts SW. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 2006; 33(7): 575-583.
18. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 2003; 63(6): 1223-1229.
19. Roth BL. Drugs and valvular heart disease. N. Engl. J. Med. 2007; 356(1): 6-9.
20. Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin. Pharmacol. 2002; 2: 6.
21. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114(3 Suppl): 195S-199S.
22. Yamamoto BK, Bankson MG. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 2005; 17(2): 87-117.
23. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 2004; 367(3): 349-354.
24. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, II, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008; 151(2): 533-543.
25. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur. J. Pharmacol. 2000; 398(1): 11-18.
26. Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro-oncology 2000; 2(2): 87-95.
27. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
28. Cote F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 2004; 10(5): 232-238.
29. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J. Biol. Chem. 1948; 176(3): 1243-1251.
30. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA 1986; 83(3): 674-678.
31. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 2006; 96(6): 678-685.
32. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 1986; 128(1-2): 41-48.
33. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Monteiro Mdo C, Goncalves MJ, Seabra V, Amado F, Carvalho F, Bastos ML. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol. 2004; 17(5): 623-632.
34. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am. J. Med. Genet. C Semin. Med. Genet. 2006; 142(2): 77-85.
35. Carvajal K, Moreno-Sanchez R. Heart metabolic disturbances in cardiovascular diseases. Arch. Med. Res. 2003; 34(2): 89-99.
36. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 1998; 273(32): 20378-20382.
37. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/ carnitine transporter. J. Pharmacol. Exp. Ther. 1999; 290(3): 1482-1492.
38. Negrao CE, Ji LL, Schauer JE, Nagle FJ, Lardy HA. Carnitine supplementation and depletion: tissue carnitines and enzymes in fatty acid oxidation. J. Appl. Physiol. 1987; 63(1): 315-321.
39. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. A threshold exists for the stimulatory effect of insulin on plasma L-carnitine clearance in humans. Am. J. Physiol. Endocrinol. Metab. 2007; 292(2): E637-641.
40. Kagawa M, Machida Y, Nishi H, Haginaka J. Enantiomeric purity determination of acetyl-L-carnitine by NMR with chiral lanthanide shift reagents. J. Pharm. Biomed. Anal. 2005; 38(5): 918-923.
41. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J. Physiol. 2007; 581(Pt 2): 431-444.
42. Allard ML, Jeejeebhoy KN, Sole MJ. The management of conditioned nutritional requirements in heart failure. Heart Fail. Rev. 2006; 11(1): 75-82.
43. Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J. Cardiovasc. Pharmacol. Ther. 2005; 10(4): 217-223.
44. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch. Biochem. Biophys. 2002; 405(1): 55-64.
45. Furuno T, Kanno T, Arita K, Asami M, Utsumi T, Doi Y, Inoue M, Utsumi K. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem. Pharmacol. 2001; 62(8): 1037-1046.
46. Chang B, Nishikawa M, Nishiguchi S, Inoue M. L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer 2005; 113(5): 719-729.
47. Reznick AZ, Kagan VE, Ramsey R, Tsuchiya M, Khwaja S, Serbinova EA, Packer L. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch. Biochem. Biophys. 1992; 296(2): 394-401.